Vir Biotechnology Q3 net loss narrows to $96.3 million; ECLIPSE 1 data due Q4
Vir Biotechnology reported third quarter 2026 results with a net loss of $96.3 million, or $0.57 per share, compared with $163.1 million, or $1.17 per share, a year earlier. The prior-year period included a non-recurring $75.0 million milestone expense, and total revenues were a loss of $188 thousand versus $240 thousand of revenue in the prior year. The company also reported topline Phase 3 ECLIPSE 1 data for hepatitis delta expected in the fourth quarter of 2026, and said its cash runway extends into the second half of 2028.
Key points
- Net loss was $96.3 million, or $0.57 per share, versus $163.1 million, or $1.17 per share, in Q3 2025
- R&D expenses were $80.0 million versus $151.5 million a year earlier, which included a $75.0 million milestone expense
- Cash, cash equivalents and investments were $901.3 million at September 30, 2026, down $106.5 million in the quarter
- Topline ECLIPSE 1 Phase 3 data expected in Q4 2026; company expects cash to fund operations into the second half of 2028
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.